Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 276 clinical trials
  • 0 views
  • 17 Jan, 2022
  • 74 locations
Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab

plus cetuximab, which resulted in a significantly prolonged overall survival versus bevacizumab in the FIRE-3 study. Following initial progression (PD1) it is recommended that the treatment be

liver metastasis
aptt
adjuvant chemotherapy
adenocarcinoma
folfiri regimen
  • 6 views
  • 09 Dec, 2021
  • 1 location
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

Anlotinib (3 weeks/cycle) + CapeOx and Bevacizumab (3 week/cycle) + CapeOx at a ratio of 1:1. This study is conducted to assess the efficacy and safety of Anlotinib and Chemotherapy as first-line treatment

  • 0 views
  • 28 Aug, 2021
  • 5 locations
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.

  • 0 views
  • 29 Nov, 2021
  • 69 locations
CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC

The objective is to compare the efficacy and safety of CAPOXIRI+BEV therapy versus FOLFOXIRI+BEV therapy as first-line therapy in patients with metastatic colorectal cancer (mCRC).

folfoxiri
oxaliplatin
liver metastasis
fluorouracil
capecitabine
  • 0 views
  • 23 Jan, 2021
  • 1 location
Bevacizumab In Hereditary Hemorrhagic Telangiectasia

This research study is studying to see whether bevacizumab may treat chronic bleeding and iron deficiency anemia in Hereditary Hemorrhagic Telangiectasia (HHT). Hereditary Hemorrhagic

  • 0 views
  • 10 Jul, 2021
  • 1 location
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma

The purpose of this study is to determine the safety and tolerability of Regorafenib in patients with recurrent or progressive glioblastoma (GBM) who have progressed on bevacizumab. Regorafenib

nitrosoureas
gliosarcoma
corticosteroids
glioblastoma multiforme
malignant glioma
  • 0 views
  • 04 Aug, 2021
  • 2 locations
Bevacizumab Treatment For Posterior Zone I ROP

Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe

  • 0 views
  • 17 Nov, 2021
  • 35 locations
Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC

To compare the efficacy and safety of gefitinib combined with bevacizumab and gefitinib in the treatment of L858R positive mutation in exon 21 of EGFR gene in advanced NSCLC.

  • 0 views
  • 25 Jan, 2021
  • 1 location
A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma

This will be a nonrandomized, single arm feasibility study with the primary goal of evaluating the safety profile of the combination of atezolizumab and bevacizumab in patients with advanced

  • 0 views
  • 05 Nov, 2021
  • 4 locations